Peer-Reviewed Publications

    Non-targeted analytical comparison of a heated tobacco product aerosol against mainstream cigarette smoke: does heating tobacco produce an inherently different set of aerosol constituents?

    Lang, G.; Henao, C.; Almstetter, M.; Arndt, D.; Goujon, C.; Maeder, S.

    Published
    Jan 13, 2024
    DOI
    10.1007/s00216-024-05126-x
    PMID
    38217698
    Link to publication
    Topic
    Summary

    Smoking-related diseases remain a significant public health concern, and heated tobacco products (HTPs) have emerged as a potential alternative to cigarettes. While several studies have confirmed that HTP aerosols contain lower levels of harmful and potentially harmful constituents (HPHCs) than cigarette smoke, less is known about constituents that are intrinsically higher in HTP aerosols. This study provides a comprehensive comparative assessment of an HTP aerosol produced with Tobacco Heating System 2.2 (THS) and comparator cigarette (CC) smoke aiming at identifying all unique or increased compounds in THS aerosol by applying a broad set of LC–MS and GC × GC–MS methods. To focus on differences due to heating versus burning tobacco, confounding factors were minimized by using the same tobacco in both test items and not adding flavorants. Of all analytical features, only 3.5%—corresponding to 31 distinctive compounds—were significantly more abundant in THS aerosol than in CC smoke. A notable subset of these compounds was identified as reaction products of glycerol. The only compound unique to THS aerosol was traced back to its presence in a non-tobacco material in the test item and not a direct product of heating tobacco. Our results demonstrate that heating a glycerol-containing tobacco substrate to the temperatures applied in THS does not introduce new compounds in the resulting aerosol compared to CC smoke which are detectable with the method portfolio applied in this study. Overall, this study contributes to a better understanding of the chemical composition of HTP aerosols and their potential impact on human health.

    Related Publications

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System 2.2

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

    Aerosol Chemistry

    Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System 2.2

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

    Aerosol Chemistry

    Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.